A5007155024- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Colorectal Cancer Treatments and Studies
- Radiomics and Machine Learning in Medical Imaging
- Head and Neck Cancer Studies
- Gastric Cancer Management and Outcomes
- Immune Cell Function and Interaction
- Cancer therapeutics and mechanisms
- Immunotherapy and Immune Responses
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
- Neuroendocrine Tumor Research Advances
- Cholangiocarcinoma and Gallbladder Cancer Studies
- CAR-T cell therapy research
- Metastasis and carcinoma case studies
- Bladder and Urothelial Cancer Treatments
- Cancer Research and Treatments
- Testicular diseases and treatments
- Cancer Diagnosis and Treatment
- Pancreatic and Hepatic Oncology Research
- Peptidase Inhibition and Analysis
- Multiple and Secondary Primary Cancers
University Hospital of Basel
2015-2024
Kantonsspital Baden
2019-2024
University of Basel
2015-2024
University Hospital of Bern
2009-2023
Hospital Base
2012-2023
Swiss Group For Clinical Cancer Research
2019-2023
Kantonsspital St. Gallen
2017-2019
Hôpital Beau-Séjour
2019
Spital STS
2019
HFR Freiburg Kantonsspital
2019
Approximately 1% of lung adenocarcinomas are driven by oncogenic ROS1 rearrangement. Crizotinib is a potent inhibitor both and ALK kinase domains.In the absence prospective clinical trial in Europe, we conducted retrospective study centers that tested for Eligible patients had stage IV adenocarcinoma, rearrangement according to fluorescent situ hybridization, received crizotinib therapy through an individual off-label use. Best response was assessed locally using RECIST (version 1.1). All...
Purpose In addition to prospective trials for non–small-cell lung cancers (NSCLCs) that are driven by less common genomic alterations, registries provide complementary information on patient response targeted therapies. Here, we present the results of an international registry patients with RET-rearranged NSCLCs, providing largest data set, our knowledge, outcomes RET-directed therapy thus far. Methods A global, multicenter network thoracic oncologists identified pathologically confirmed...
For patients with resectable stage IIIA(N2) non-small-cell lung cancer, neoadjuvant chemotherapy cisplatin and docetaxel followed by surgery resulted in a 1-year event-free survival (EFS) rate of 48% the SAKK 16/00 trial is an accepted standard care. We investigated additional benefit perioperative treatment durvalumab.Neoadjuvant consisted three cycles 100 mg/m2 85 once every 3 weeks two doses durvalumab 750 mg 2 weeks. Durvalumab was continued for 1 year after surgery. The primary end...
<h3>Background</h3> Immune checkpoint inhibitors targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death 1 (PD-1) have been recently approved for treatment of patients with metastatic melanoma non-small lung cancer (NSCLC). Despite important clinical benefits, these therapies are associated a diverse spectrum immune-related adverse events (irAEs) that typically transient, but occasionally severe or even fatal. <h3>Case presentation</h3> This autopsy case...
Immune checkpoint inhibition with ipilimumab has revolutionized cancer immunotherapy and significantly improved outcomes of patients advanced malignant melanoma. Local peripheral treatments (LPT), such as radiotherapy or electrochemotherapy, have been shown to modulate systemic immune responses, preliminary data raised the hypothesis that combination LPT blockade might be beneficial. Clinical from 127 consecutively treated melanoma at four centers in Germany Switzerland were analyzed....
B lymphocytes are important players in immune responses to cancer. However, their composition and function head neck squamous cell carcinoma (HNSCC) has not been well described. Here, we analyzed subsets HNSCC (n = 38), non-cancerous mucosa 14) peripheral blood from patients 38) healthy controls 20) by flow cytometry. Intratumoral cells contained high percentages of activated (CD86+), antigen-presenting (CD86+/CD21−) memory (IgD−/CD27+). T follicular helper (CD4+/CXCR5+/CD45RA−/CCR7−) as key...
<h3>Background</h3> Immune checkpoint inhibiting antibodies were introduced into routine clinical practice for cancer patients. Checkpoint blockade has led to durable remissions in some patients, but may also induce immune-related adverse events (irAEs). Lung patients show an increased risk complications, when infected with influenza viruses. Therefore, vaccination is recommended. However, the efficacy and safety of during its influence on irAEs unclear. Similarly, vaccinations T...
The composition of tumor-infiltrating lymphocytes (TIL) reflects biology and immunogenicity cancer. Here, we characterize T-cell subsets expression immune checkpoint molecules in head neck squamous cell carcinoma (HNSCC). We analyzed TIL primary tumors (n = 34), blood (peripheral mononuclear cells (PBMC); n 34) non-cancerous mucosa 7) 34 treatment-naïve HNSCC patients PBMC 15 healthy controls. Flow cytometry analyses revealed a highly variable infiltration mainly an effector memory phenotype...
In non-small cell lung cancer (NSCLC), immune checkpoint inhibitors (ICIs) significantly improve overall survival (OS). Tumor mutational burden (TMB) has emerged as a predictive biomarker for patients treated with ICIs. Here, we evaluated the power of TMB measured by Oncomine™ Mutational Load targeted sequencing assay in 76 NSCLC was assessed retrospectively receiving ICI therapy. Clinical data (RECIST 1.1) were collected and classified having either durable clinical benefit (DCB) or no...
Abstract Purpose: Designed ankyrin repeat proteins (DARPins) hold great promise as a new class of binding molecules to overcome the limitations antibodies for biomedical applications. Here, we assessed potential an epithelial cell adhesion molecule (EpCAM)–specific DARPin (Ec4) tumor targeting fusion toxin with Pseudomonas aeruginosa exotoxin A. Experimental design: Ec4 was genetically fused truncated form A (ETA″) and expressed in Escherichia coli. The cytotoxicity Ec4-ETA″ measured against...
PURPOSE The integration of immunotherapy in the perioperative setting muscle-invasive urothelial carcinoma (MIUC) appears promising. SAKK 06/17 investigated addition neoadjuvant durvalumab to gemcitabine/cisplatin (GC) chemotherapy followed by radical surgery and adjuvant checkpoint inhibition with durvalumab. PATIENTS AND METHODS was an investigator-initiated, open-label, single-arm phase II study including cisplatin-fit patients stage cT2-T4a cN0-1 operable MIUC. Four cycles GC combination...
MicroRNAs are small, noncoding RNAs that suppress gene expression by binding to the 3' untranslated region (UTR) and thereby repress translation or decrease messenger RNA stability. Inhibitor of differentiation 1 (ID1) is a putative stem-cell involved in invasion angiogenesis. We previously showed ID1 regulated Src kinases, overexpressed human lung adenocarcinoma, targeted Src-dependent microRNAs. The current study focused on association between miR-381 adenocarcinoma.An 3'UTR-luciferase...
Tumor-infiltrating lymphocytes (TILs) are correlated to prognosis of several kinds cancer. Most studies focused on T cells, while the role tumor-associated B cells (TABs) has only recently gained more attention. TABs contain subpopulations with distinct functions, potentially promoting or inhibiting immune responses. This study provides a detailed analysis in gastro-esophageal adenocarcinoma (EAC). Flow cytometric analyses single cell suspensions tumor samples, mucosa, lymph nodes and...